Stocks-EBS-Emergent BioSolutions Inc

EBS Emergent BioSolutions Inc

0 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Emergent BioSolutions Inc's revenues decreased by 37.47% and amounted to 1.12B. Net income decreased by 196.93% to -223.80M. Net assets decreased by 14.58% to 1.38B and EPS decreased from 4.27 to -4.47.
EBS's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
27.82%
Net Profit Margin
4.50%
Operating Margin
-17.62%
Return On Investment
3.39%